113 related articles for article (PubMed ID: 18826989)
1. Hormone therapy and risk of myocardial infarction: a national register study.
Løkkegaard E; Andreasen AH; Jacobsen RK; Nielsen LH; Agger C; Lidegaard Ø
Eur Heart J; 2008 Nov; 29(21):2660-8. PubMed ID: 18826989
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of stroke in hypertensive women using hormone therapy: analyses based on the Danish Nurse Study.
Løkkegaard E; Jovanovic Z; Heitmann BL; Keiding N; Ottesen B; Hundrup YA; Obel EB; Pedersen AT
Arch Neurol; 2003 Oct; 60(10):1379-84. PubMed ID: 14568807
[TBL] [Abstract][Full Text] [Related]
3. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study.
Lindhardsen J; Ahlehoff O; Gislason GH; Madsen OR; Olesen JB; Torp-Pedersen C; Hansen PR
Ann Rheum Dis; 2011 Jun; 70(6):929-34. PubMed ID: 21389043
[TBL] [Abstract][Full Text] [Related]
4. Hormone therapy and ovarian borderline tumors: a national cohort study.
Mørch LS; Løkkegaard E; Andreasen AH; Kjær SK; Lidegaard Ø
Cancer Causes Control; 2012 Jan; 23(1):113-20. PubMed ID: 22037908
[TBL] [Abstract][Full Text] [Related]
5. The myeloperoxidase gene and its influence on myocardial infarction in a Swedish population: protective role of the -129A allele in women.
Zotova E; Lyrenäs L; de Faire U; Morgenstern R; Gigante B; Bennet AM
Coron Artery Dis; 2009 Aug; 20(5):322-6. PubMed ID: 19543083
[TBL] [Abstract][Full Text] [Related]
6. Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register.
Nilsson PM; Cederholm J; Eeg-Olofsson K; Eliasson B; Zethelius B; Fagard R; Gudbjörnsdóttir S;
Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):506-12. PubMed ID: 19561510
[TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy and risk of non-fatal stroke.
Pedersen AT; Lidegaard O; Kreiner S; Ottesen B
Lancet; 1997 Nov; 350(9087):1277-83. PubMed ID: 9357407
[TBL] [Abstract][Full Text] [Related]
8. Hormone therapy and ovarian cancer.
Mørch LS; Løkkegaard E; Andreasen AH; Krüger-Kjaer S; Lidegaard O
JAMA; 2009 Jul; 302(3):298-305. PubMed ID: 19602689
[TBL] [Abstract][Full Text] [Related]
9. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
[TBL] [Abstract][Full Text] [Related]
10. The influence of hormone therapies on type I and II endometrial cancer: A nationwide cohort study.
Mørch LS; Kjaer SK; Keiding N; Løkkegaard E; Lidegaard Ø
Int J Cancer; 2016 Mar; 138(6):1506-15. PubMed ID: 26421912
[TBL] [Abstract][Full Text] [Related]
11. Hormone replacement therapy in Denmark, 1995-2004.
Løkkegaard E; Lidegaard O; Møller LN; Agger C; Andreasen AH; Jørgensen T
Acta Obstet Gynecol Scand; 2007; 86(11):1342-51. PubMed ID: 17963062
[TBL] [Abstract][Full Text] [Related]
12. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
van Staa TP; Rietbrock S; Setakis E; Leufkens HG
J Intern Med; 2008 Nov; 264(5):481-92. PubMed ID: 18624902
[TBL] [Abstract][Full Text] [Related]
13. Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms?
Haskell SG; Bean-Mayberry B; Gordon K
Menopause; 2009; 16(3):494-9. PubMed ID: 19182695
[TBL] [Abstract][Full Text] [Related]
14. Myocardial infarction risk and hormone replacement: differences between products.
de Vries CS; Bromley SE; Farmer RD
Maturitas; 2006 Feb; 53(3):343-50. PubMed ID: 16040209
[TBL] [Abstract][Full Text] [Related]
15. Cancer issues.
Marsden J; Sturdee D
Best Pract Res Clin Obstet Gynaecol; 2009 Feb; 23(1):87-107. PubMed ID: 19036643
[TBL] [Abstract][Full Text] [Related]
16. Income as mediator of the effect of occupation on the risk of myocardial infarction: does the income measurement matter?
Andersen I; Gamborg M; Osler M; Prescott E; Diderichsen F
J Epidemiol Community Health; 2005 Dec; 59(12):1080-5. PubMed ID: 16286499
[TBL] [Abstract][Full Text] [Related]
17. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
18. Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin.
Juhaeri J; Gao S; Dai WS
Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):497-503. PubMed ID: 19326365
[TBL] [Abstract][Full Text] [Related]
19. Hormone therapy and risk of myocardial infarction.
Lowe G
Womens Health (Lond); 2009 Jan; 5(1):29-31. PubMed ID: 19102637
[TBL] [Abstract][Full Text] [Related]
20. Initiating therapy with antidepressants after discontinuation of hormone therapy.
Citarella A; Andersen M; Sundström A; Bardage C; Hultman CM; Kieler H
Menopause; 2013 Feb; 20(2):146-51. PubMed ID: 22929038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
